References
- WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours.
WHO Classification of Tumours series, 5th edition, volume 11 [Internet; beta version ahead of print] . Lyon, France: International Agency for Research on Cancer; 2022 [cited 2023 Jul 22]. Available from:https://tumourclassification.iarc.who.int . - Arber DA, Orazi A. Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future. Am J Hematol. 2025;100(Suppl 4):5–15. DOI: 10.1002/ajh.27656
- Patel RA, Hall DA, Eichenseer S, Bailey M. Movement Disorders and Hematologic Diseases. Mov Disord Clin Pract. 2020;8(2):193–207. DOI: 10.1002/mdc3.13129
- Blumenthal DT, Glenn MJ. Neurologic manifestations of hematologic disorders. Neurol Clin. 2002;20(1):265–81, viii. DOI: 10.1016/S0733-8619(03)00063-X
- Schroeder LE, Snow E, Chen C, Addo A, Mohammadzadeh N, Recht L, et al. Cancer-Related Movement Disorders: A Scoping Review and Diagnostic Approach. Neuro-Oncology Practice. 2025:npaf062. DOI: 10.1093/nop/npaf062
- Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40. DOI: 10.1016/S1474-4422(08)70060-7
- McKeon A, Tracy J. Paraneoplastic movement disorders. Handb Clin Neurol. 2024;200:211–227. PMID: 38494279. DOI: 10.1016/B978-0-12-823912-4.00004-9
- Grillo P, DI Giuliano F, Massa R, Mercuri NB, Schirinzi T. Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. Neurol Sci. 2021;42(3):905–910. Epub 2021 Jan 14. PMID: 33443666. DOI: 10.1007/s10072-020-04985-3
- Nothrop R, Lee W, Lee D, Gilligan AK. Chorea as a paraneoplastic syndrome heralding the transformation of non-Hodgkin lymphoma. Med J Aust. 2021;214(3):114–115.e1. DOI: 10.5694/mja2.50918
- Sanderson JB, Lin YH, Su K, Wang Y, Portuguese A, Gauthier J, Durbin M, Banerjee R. Treatment-Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T-Cell Therapy. Mov Disord Clin Pract. 2025. Epub ahead of print. DOI: 10.1002/mdc3.70452
- Cedergren Weber G, Timpka J, Rydelius A, Bengzon J, Odin P. Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. Brain and Behavior. 2023;13(8). DOI: 10.1002/brb3.3151
- Mancone S, Selvadurai C, Baehring J, Patel A. Choreoathetosis in the Setting of Human Herpesvirus-6 Infection in a Transplant Recipient. Tremor Other Hyperkinet Mov (N Y). 2021;11:40. DOI: 10.5334/tohm.657
- Garg RK, Jain A, Pandey S, Paliwal VK, Singhal S. Spectrum of Movement Disorders in Hematological Malignancies and Myeloproliferative Disorders: A Systematic Review. PROSPERO 2025 CRD420251168610. Available from
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251168610 . - The Movement Disorder Society. About Movement Disorders: View clinical information, resources, tools and education about common movement disorders. Downloaded from
https://www.movementdisorders.org/MDS/About/Movement-Disorder-Overviews.htm . Assessed on 31st October, 2025. - Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63. DOI: 10.1136/bmjebm-2017-110853
- Sharma A, Dube S, Mountjoy L, Ertz-Archambault N, Porter A, Mrugala MM. Psychiatric Disturbance or Parkinsonism as a Presentation of CNS Lymphoma: Observational Retrospective Study and Review of Literature. Am J Clin Oncol. 2020;43(10):727–733. DOI: 10.1097/COC.0000000000000738
- Deckert M, Brunn A, Montesinos-Rongen M, Terreni MR, Ponzoni M. Primary lymphoma of the central nervous system–a diagnostic challenge. Hematol Oncol. 2014;32(2):57–67. DOI: 10.1002/hon.2087
- Siegal T, Benouaich-Amiel A, Bairey O. Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev. 2022 May;53:100910. DOI: 10.1016/j.blre.2021.100910
- Sobol U, Stiff P. Neurologic aspects of plasma cell disorders. Handb Clin Neurol. 2014;120:1083–99. DOI: 10.1016/B978-0-7020-4087-0.00073-5
- Zhao-Fleming H, Rezk M, Shah S, Gupta P, Zekeridou A, Flanagan EP, Pittock SJ, McKeon A, Dubey D. Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice. Neurol Neuroimmunol Neuroinflamm. 2024;11(6):
e200316 . DOI: 10.1212/NXI.0000000000200316 - Baral MR, Bhandari S. Approach to hyperleukocytosis and leukostasis- inpatient management strategies. J Hosp Med. 2025. Epub ahead of print. DOI: 10.1002/jhm.70199
- Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol. 1993;14(4):1014–6.
- Mauermann ML, Southerland AM. Hematologic Disorders and the Nervous System. Continuum (Minneap Minn). 2023;29(3):826–847. DOI: 10.1212/CON.0000000000001238
- Kerstens J, Titulaer MJ. Overview of treatment strategies in paraneoplastic neurological syndromes. Handb Clin Neurol. 2024;200:97–112. DOI: 10.1016/B978-0-12-823912-4.00015-3
- Verma N, Jaffer MH, Kolli AS, Mokhtari S. Updates in the Management of Paraneoplastic Syndrome. Semin Neurol. 2024;44(1):36–46. DOI: 10.1055/s-0043-1777353
- Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity–focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92–105. DOI: 10.1038/nrclinonc.2015.152